Role of α 2- Heremans and Schmid glycoproteins (α 2-HSG) as a threshold concept of calcification in patients with Chronic Kidney Disease
DOI:
https://doi.org/10.61841/x5vsf903Keywords:
Fetuin, CKD, CVDAbstract
Fetuin A (FA, AHSG or a 2-HS glycoprotein) is a glycoprotein mainly produced by liver. FA can inhibit the de novo formation and precipitation of the apatite precursor mineral (namely calcium phosphate). Therefore, FA can prevent undesirable calcification in the circulation without inhibiting bone mineralization.Cardiovascular disease (CVD) in chronic kidney disease (CKD) is explained in part by traditional cardiovascular risk factors; by uremia-specific factors, abnormalities of mineral metabolism, and the vascular calcification process. Lower serum concentrations of FA was independently associated with risk of cardiovascular. The main aims of the study were to follow the role of FA in the progression of renal disease which promoted cardiovascular disease. Improving the understanding of the mechanisms of action might undoubtedly lead to well therapies to combat the destructive effects in CKD.The present work included a cross sectional study for a group of 80 subject patients with end stage chronic kidney disease were selected from hemodialysis unit at the Nephrology Department, Al Hussein Teaching medical city. Blood samples were collected from dialysis unit from fistule pre heparinized, pre dialysed patients. Enzyme Link Immunosorbat Assay system (ELISA) was performed using Sandawich method to measure the concentrations of serum Human Fetuin A and Parathyriod hormone (PTH). Significant differences in continuous variables among the parameters were confirmed through analytical statistical tests.Associations of characteristic parameters with serum Fetuin A levels were shown high significant difference specially with Creatinine, Urea, K, increased levels of these parameters were significantly associated with decreased FA levels (P<0.001), while ; in spite of the normal range of (Na, Ca, P and Albumin) levels, there was a significantly associated with decreased FA levels (P<0.001). Analysis of correlation illustrated that FA has a positive relationship with Hb, serum Albumin levels and serum K levels (P<0.001), while inverse and significant correlations of FA was manifested with serum Urea, Creatinine , Phosphorous l, Na, Ca levels, all have (P<0.001).In CKD patients, FA levels were decreased. Serum concentrations of FA were decreased in patients with end stage renal disease on dialysis, and lower serum concentrations were independently associated with risk of cardiovascular (vascular calcification) which increase the mortality in this population, fetuin A was strongly independent prognostic factor of the severity of CVD.
Downloads
References
1. Kumar, V., & Cotran, R. S. (1994). Robbins' basic pathology. Archives of Pathology and Laboratory Medicine, 118(2), 203-203.
2. Smith, E. R., Ford, M. L., Tomlinson, L. A., Rajkumar, C., McMahon, L. P., & Holt, S. G. (2012). Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrology Dialysis Transplantation, 27(5), 1957- 1966.
3. Amann, K. (2008). Media calcification and intima calcification are distinct entities in chronic kidney disease. Clinical Journal of the American Society of Nephrology, 3(6), 1599-1605.
4. Human FETUA (fetuinA) ELISA Kit Catalog No.:E-EL-H0386, Elabscience., USA.
5. Caglar, K., Yilmaz, M. I., Saglam, M., Cakir, E., Acikel, C., Eyileten, T., ... & Axelsson, J. (2008). Short- term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clinical Journal of the American Society of Nephrology, 3(1), 61-68.
6. Smith, E. R., Ford, M. L., Tomlinson, L. A., Rajkumar, C., McMahon, L. P., & Holt, S. G. (2012). Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrology Dialysis Transplantation, 27(5), 1957- 1967.
7. Mizobuchi, M., Towler, D., & Slatopolsky, E. (2009). Vascular calcification: the killer of patients with chronic kidney disease. Journal of the American Society of Nephrology, 20(7), 1453-1464.
8. Kanbay, M., Nicoleta, M., Selcoki, Y., Ikizek, M., Aydin, M., Eryonucu, B., ... & Covic, A. (2010). Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clinical Journal of the American Society of Nephrology, 5(10), 1780- 1786.
9. Al-Hakeim, H. K., & Ali, R. A. M. (2015). Proteinuria as the most relevant parameter affecting Fetuin-A levels in preeclampsia. Acta facultatis medicae Naissensis, 32(4), 267-277.
10. Maharem, D. A., Gomaa, S. H., El Ghandor, M. K., Mohamed, E. I., Matrawy, K. A., Zaytoun, S. S., & Nomeir, H. M. (2013). Association of serum fetuin-A and fetuin-A gene polymorphism in relation to mineral and bone disorders in patients with chronic kidney disease. Egyptian Journal of Medical Human Genetics, 14(4), 337-352.
11. Schoppet, M., Shroff, R. C., Hofbauer, L. C., & Shanahan, C. M. (2008). Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?. Kidney international, 73(4), 384-390.
12. Moe, S. M., & Chen, N. X. (2004). Pathophysiology of vascular calcification in chronic kidney disease.
Circulation research, 95(6), 560-567.
13. Axelsson, J., Wang, X., Ketteler, M., Qureshi, A. R., Heimbürger, O., Bárány, P., ... & Stenvinkel, P. (2008). Is fetuin-A/α2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?. American journal of nephrology, 28(4), 669-676.
14. Ix, J. H., & Sharma, K. (2010). Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. Journal of the American Society of Nephrology, 21(3), 406-412.
15. Nimptsch, K., Janke, J., Pischon, T., & Linseisen, J. (2015). Association between dietary factors and plasma fetuin-A concentrations in the general population. British Journal of Nutrition, 114(8), 1278-1285.
16. Liao, M. T., Sung, C. C., Hung, K. C., Wu, C. C., Lo, L., & Lu, K. C. (2012). Insulin resistance in patients with chronic kidney disease. BioMed Research International, 2012.
17. Jahnen-Dechent, W., Schäfer, C., Heiss, A., & Grötzinger, J. (2001). Systemic inhibition of spontaneous calcification by the serum protein α 2-HS glycoprotein/fetuin. Zeitschrift für Kardiologie, 90(3), 47-56.
18. Cai, M. M., Smith, E. R., & Holt, S. G. (2015). The role of fetuin-A in mineral trafficking and deposition.
BoneKEy reports, 4.
19. Habraken, W. J., Tao, J., Brylka, L. J., Friedrich, H., Bertinetti, L., Schenk, A. S., ... & Laven, J. (2013). Ion-association complexes unite classical and non-classical theories for the biomimetic nucleation of calcium phosphate. Nature communications, 4, 1507.
20. Garnett, J., & Dieppe, P. (1990). The effects of serum and human albumin on calcium hydroxyapatite crystal growth. Biochemical Journal, 266(3), 863.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
